stockrowBelite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
- EPS
- −40.0%
- Free cash flow
- +64.7%
Quarter to June 2026, against a year earlier
Follow BLTE
Alert me
Belite Bio, Inc. Sponsored ADR (BLTE) Return on assets
Belite Bio, Inc. Sponsored ADR's return on assets over the twelve months to 30 June 2026 was −21.6%, down 5.0 percentage points from fiscal 2025 (−16.6%). Over the past ten years it has ranged from −45.5% (fiscal 2023) to 0.00% (fiscal 2020); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −16.6% | 12.65 |
| FY2024 | −29.3% | 16.25 |
| FY2023 | −45.5% | (5.14) |
| FY2022 | −40.4% | 3.45 |
| FY2021 | −43.9% | (43.85) |
| FY2020 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 2.77% |
| PTCT PTC Therapeutics, Inc. compare | −3.62% |
| ORKA Oruka Therapeutics, Inc. compare | −17.8% |
| IONS Ionis Pharmaceuticals, Inc. compare | −18.9% |
| BLTE Belite Bio, Inc. Sponsored ADR | −21.6% |
| CGON CG Oncology, Inc. compare | −25.1% |
| IMVT Immunovant, Inc. compare | −71.1% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −99.8% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)